Huntington Disease: Difference between revisions

No edit summary
No edit summary
Line 12: Line 12:
== Mechanism of Injury / Pathological Process<br>  ==
== Mechanism of Injury / Pathological Process<br>  ==


add text here relating to the mechanism of injury and/or pathology of the condition<br>  
The most obvious neuropathology in HD occurs within the neostriatum, comprising gross atrophy of the caudate nucleus and putamen, accompanied by selective neuronal loss and astrogliosis (an abnormal increase in the number of astrocytes). Marked neuronal loss also is seen in deep layers of the cerebral cortex. Other regions, including the globus pallidus, thalamus, subthalamic nucleus, substantia nigra, and cerebellum, show varying degrees of atrophy depending on the stage of the disease.<br>  


== Clinical Presentation  ==
== Clinical Presentation  ==
Line 50: Line 50:
Measurement of the bicaudate diameter (ie, the distance between the heads of the 2 caudate nuclei) by CT scan or MRI is considered to be a reliable marker of HD<ref>Stober T, Wussow W, Schimrigk K. Bicaudate diameter--the most specific and simple CT parameter in the diagnosis of Huntington's disease. Neuroradiology. 1984. 26(1):25-8</ref>.<br>  
Measurement of the bicaudate diameter (ie, the distance between the heads of the 2 caudate nuclei) by CT scan or MRI is considered to be a reliable marker of HD<ref>Stober T, Wussow W, Schimrigk K. Bicaudate diameter--the most specific and simple CT parameter in the diagnosis of Huntington's disease. Neuroradiology. 1984. 26(1):25-8</ref>.<br>  


Genetic testing (reported as the CAG repeat number for each allele) is now widlyavailable.<br>Genetic testing may not be necessary in a patient with a typical clinical picture and a genetically proven family history of HD.<br>
Genetic testing (reported as the CAG repeat number for each allele) is now widlyavailable.<br>Genetic testing may not be necessary in a patient with a typical clinical picture and a genetically proven family history of HD.<br>  


== Management / Interventions<br>  ==
== Management / Interventions<br>  ==

Revision as of 22:25, 14 September 2015

Original Editor - Wendy Walker

Lead Editors  

General[edit | edit source]

Huntington disease (HD) is an incurable, adult-onset, progressive deurodegenerative disorder which presents with involuntary movements, dementia, and behavioral changes[1].

HD is named after George Huntington, the physician who described it as hereditary chorea in 1872[2].

Mechanism of Injury / Pathological Process
[edit | edit source]

The most obvious neuropathology in HD occurs within the neostriatum, comprising gross atrophy of the caudate nucleus and putamen, accompanied by selective neuronal loss and astrogliosis (an abnormal increase in the number of astrocytes). Marked neuronal loss also is seen in deep layers of the cerebral cortex. Other regions, including the globus pallidus, thalamus, subthalamic nucleus, substantia nigra, and cerebellum, show varying degrees of atrophy depending on the stage of the disease.

Clinical Presentation[edit | edit source]

The clinical manifestations of HD usually present between the ages of 35 and 45 years, but can begin at any age from childhood to old age.

The clinical features of Huntington disease (HD) include a movement disorder, a cognitive disorder, and a behavioral disorder[2]. Patients may present with one or all disorders in varying degrees. Early stages of HD are characterized by deficits in short-term memory, followed by motor dysfunction and a variety of cognitive changes in the intermediate stages of dementia[3].

Movement Disorder[edit | edit source]

Chorea (derived from the Greek word meaning to dance) is the most common movement disorder seen in HD.

Initially, mild chorea may cause the patient to appear restless, as if they are fidgeting. This progresses, and severe chorea may appear as uncontrollable writhing and flailing of the extremities, which interferes with function.

As the disease progresses, chorea coexists with ,and gradually is replaced by, dystonia and parkinsonian features, such as bradykinesia, rigidity, and postural instability.

In advanced disease, patients develop an akinetic-rigid syndrome, with minimal or no chorea. Other late features are spasticity, clonus, and extensor plantar responses.

The clinical manifestations of HD usually present between the ages of 35 and 45 years, but can begin at any age from childhood to old age.

Dysarthria and dysphagia are common. Abnormal eye movements may be seen early in the disease. Other movement disorders, such as tics and myoclonus, may be seen in patients with HD.

Cognitive Effects[edit | edit source]

Cognitive decline is characteristic of HD, but the rate of progression among individual patients can vary considerably. Dementia and the psychiatric features of HD are frequently the earliest symptoms[4]

The dementia syndrome associated with HD includes early onset behavioral changes, such as irritability, untidiness, and loss of interest. Slowing of cognition, impairment of intellectual function, and memory disturbances usually occur later[3].

Mood Effects[edit | edit source]

Depression is the most common mood effect[3], with a small percentage of patients experiencing episodic bouts of mania characteristic of bipolar disorder.

Patients with HD also can develop psychosis, obsessive-compulsive symptoms, sexual and sleep disorders, as well as changes in personality. 

Diagnostic Procedures[edit | edit source]

Measurement of the bicaudate diameter (ie, the distance between the heads of the 2 caudate nuclei) by CT scan or MRI is considered to be a reliable marker of HD[5].

Genetic testing (reported as the CAG repeat number for each allele) is now widlyavailable.
Genetic testing may not be necessary in a patient with a typical clinical picture and a genetically proven family history of HD.

Management / Interventions
[edit | edit source]

add text here relating to management approaches to the condition

Differential Diagnosis
[edit | edit source]

Chorea Gravidarum

Multiple Sclerosis

Systemic Lupus Erythematosus (SLE)

Neuroacanthocytosis

Key Evidence[edit | edit source]

add text here relating to key evidence with regards to any of the above headings

Resources
[edit | edit source]

add appropriate resources here

Case Studies[edit | edit source]

add links to case studies here (case studies should be added on new pages using the case study template)

Recent Related Research (from Pubmed)[edit | edit source]

Extension:RSS -- Error: Not a valid URL: Feed goes here!!|charset=UTF-8|short|max=10

References[edit | edit source]

References will automatically be added here, see adding references tutorial.

  1. Folstein SE. Huntington's Disease: A Disorder of Families. The Johns Hopkins University Press. 1989
  2. 2.0 2.1 Huntington G. On chorea. Med Surg Report. 1872. 26:320
  3. 3.0 3.1 3.2 Ho A, Hocaoglu M. Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective. Clin Genet. Sep 2011
  4. Loy CT, McCusker EA. Is a motor criterion essential for the diagnosis of clinical huntington disease?. PLoS Curr. Apr 11 2013. 5
  5. Stober T, Wussow W, Schimrigk K. Bicaudate diameter--the most specific and simple CT parameter in the diagnosis of Huntington's disease. Neuroradiology. 1984. 26(1):25-8